GRCE

Grace Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001444192

$2.20 -4.35% $29.5M

High Impact Filing (7/10)

Vol

Market Cap$29.5M

Cap SizeNano Cap

Analyst ConsensusStrong Buy (88%)

Inst. Holders14 funds

Inst. Value$10.7M

Inst. Activity2 buys / 1 sells

Reddit Sentiment60° Warm

SEC Reports3

Press Releases1

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001444192·Prev Close $2.30

Recent Activity

Jun 5, 2026 SEC

Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operations effective June 5

8-K — Impact 2/10

Apr 27, 2026 SEC

Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Response Letter (CRL) f

8-K — Impact 7/10

Apr 23, 2026 SEC

Grace Therapeutics received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for GTx-104

8-K — Impact 7/10

Inst.

Cerity Partners LLC — DOUBLED

849,055 shares ($3.9M)

Inst.

RENAISSANCE TECHNOLOGIES LLC — ADD

243,910 shares ($1.1M)

Apr 23, 2026 other

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemis

Apr 14, 2026 Press

Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimo

Impact 7/10

Price Targets

$5.87 +166.7% upside Strong Buy

Current $2.20 Low $3.91 Median $5.87 High $7.82 2 analysts

$3.91 $7.82

Analyst Ratings

Strong Buy88% buy · 8 analysts

2Strong Buy

5Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Apr 24, 2026	TD Cowen	MAINTAIN	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.20 ▲ +16.3%	$-0.20 — $-0.20	-249% YoY	1
Next Q	$-0.20 ▲ +11.6%	$-0.20 — $-0.20	29% YoY	1
Current FY	$-1.03 ▲ +11.1%	$-1.30 — $-0.75	5% YoY	2
Next FY	$-0.95 ▼ -7.9%	$-1.09 — $-0.81	7% YoY	2

Latest Reports

NEUTRAL 8-K 2/10

Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operations effective June 5

Jun 5, 2026

BEARISH 8-K 7/10

Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Response Letter (CRL) f

Apr 27, 2026

BULLISH Press 7/10

Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimo

Apr 14, 2026

Top Institutional Holders

Fund	Value	Move
Cerity Partners LLC	$3.9M	DOUBLED
BANK OF AMERICA CORP	$2.3M	—
VANGUARD CAPITAL MANAGEMENT LLC	$1.9M	—
RENAISSANCE TECHNOLOGIES LLC	$1.1M	ADD
CITADEL ADVISORS LLC	$457.2K	—

Reddit Sentiment

60°

Warm

Bearish Neutral Bullish

1 mentions 1 bullish 0 bearish

14 institutional holders with $10.7M total value (2,315,659 shares) as of 2026-Q1. Top holders: Cerity, BANK, VANGUARD. Net buying activity: 2 institutions added/increased vs 1 reduced.

Top Institutional Holders — 2026-Q1

#	Fund	Shares	Value	% of Tracked	Last Move
1	Cerity Partners LLC	849,055	$3.9M	36.7%	DOUBLED +100.8%
2	BANK OF AMERICA CORP /DE/	494,723	$2.3M	21.4%	—
3	VANGUARD CAPITAL MANAGEMENT LLC	401,656	$1.9M	17.3%	—
4	RENAISSANCE TECHNOLOGIES LLC	243,910	$1.1M	10.5%	ADD +87.9%
5	CITADEL ADVISORS LLC	98,742	$457.2K	4.3%	—
6	MARSHALL WACE, LLP	91,416	$423.3K	3.9%	—
7	SUSQUEHANNA INTERNATIONAL GROUP, LLP	62,200	$288.0K	2.7%	—
8	SUSQUEHANNA INTERNATIONAL GROUP, LLP	50,600	$234.3K	2.2%	—
9	VANGUARD FIDUCIARY TRUST CO	8,750	$40.5K	0.4%	—
10	GROUP ONE TRADING LLC	5,000	$23.1K	0.2%	—
11	MORGAN STANLEY	4,548	$21.1K	0.2%	NEAR_EXIT -82.1%
12	NATIONAL BANK OF CANADA /FI/	2,716	$12.6K	0.1%	—
13	WELLS FARGO & COMPANY/MN	1,800	$8.3K	0.1%	—
14	ROYAL BANK OF CANADA	543	$3.0K	0.0%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
Cerity Partners LLC	DOUBLED	422,732	849,055	+100.8%	$3.9M	2026-Q1
RENAISSANCE TECHNOLOGIES LLC	ADD	129,781	243,910	+87.9%	$1.1M	2026-Q1
MORGAN STANLEY	NEAR_EXIT	25,448	4,548	-82.1%	$21.1K	2026-Q1
RENAISSANCE TECHNOLOGIES LLC	ADD	84,561	129,781	+53.5%	$449.0K	2025-Q4
MORGAN STANLEY	DOUBLED	1,848	25,448	+1277.1%	$88.0K	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	27,625	84,561	+206.1%	$251.7K	2025-Q3
VANGUARD GROUP INC	ADD	255,400	409,100	+60.2%	$1.2M	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	TRIM	42,181	27,625	-34.5%	$82.0K	2025-Q2

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.

NEUTRAL 8-K 2/10

Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operati

Jun 5, 2026

BEARISH 8-K 7/10

Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Res

Apr 27, 2026

BEARISH 8-K 7/10

Grace Therapeutics received a Complete Response Letter (CRL) from the FDA for its New Drug Applicati

Apr 23, 2026

BULLISH 7/10

Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV

Apr 14, 2026

Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$5.87 mean target +166.7% upside Strong Buy (3.00)

$3.91 Low $7.82 High

Metric	Value
Current Price	$2.20
Target Low	$3.91
Target Mean	$5.87
Target Median	$5.87
Target High	$7.82
# Analysts	2
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-03-31	$-0.20	$-0.20	$-0.20	-249.3%	+16.3%	1↑ 0↓	$0.0B	0.0%	1
Next Q 2026-06-30	$-0.20	$-0.20	$-0.20	29.2%	+11.6%	1↑ 0↓	$0.0B	0.0%	1
Current FY 2026-03-31	$-1.03	$-1.30	$-0.75	5.4%	+11.1%	2↑ 0↓	$0.0B	0.0%	2
Next FY 2027-03-31	$-0.95	$-1.09	$-0.81	7.4%	-7.9%	1↑ 1↓	$0.0B	0.0%	2

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.205
7d ago	$-0.245	+0.040
30d ago	$-0.245	+0.040
60d ago	$-0.245	+0.040
90d ago	$-0.491	+0.286

1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Apr 24, 2026	TD Cowen	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	2	5	1	88%
May 1, 2026	2	5	1	88%
Apr 1, 2026	2	5	1	88%
Mar 1, 2026	2	5	1	88%
Feb 1, 2026	2	5	1	88%
Jan 1, 2026	2	5	1	88%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

60°

Warm

Bearish Neutral Bullish

1 mentions 1 bullish 0 bearish 1 time period

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Bearish	Threads
Feb 27, 2026	1	60° Warm	1	0	1

Recent Reddit Threads

r/pennystocks Bullish 3mo ago

RCKT FLYING UP 16% TODAY

▲ 1 💬 1 ⚡ 0.0

Apr 23, 2026

other

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical

Apr 23, 2026

fda_pdufa

PDUFA: GRCE — GTx-104 in aneurysmal Subarachnoid Hemorrhage (aSAH) — 2026-04-23

FDA target action date 2026-04-23 for GRCE (Grace Therapeutics, Inc.). Drug: GTx-104. Indication: aneurysmal Subarachnoid Hemorrhage (aSAH). FDA estab

Apr 22, 2026

short_volume

Short Volume: GRCE — 62.0% short (0.4M / 0.6M)

Short: 367,328 | Exempt: 39,538 | TRF Vol: 592,278 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)

Apr 14, 2026

fda

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company),

Mar 13, 2026

short_interest

FTD: GRCE — 269,245 shares ($1.1M) failed to deliver

Settlement: 20260313, Price: $4.06, FTD Value: $1,093,134.7, GRACE THERAPEUTICS, INC. COMMO